Lifecore Biomedical Stock Surges on Acquisition News, Analyst Downgrades to Hold

Font: Financial Modeling Prep  • Sep 28, 2026

• Lifecore Biomedical (NASDAQ: LFCR)'s stock surged 55.24% following an acquisition announcement, reaching $6.52 per share.
• Analyst Matthew Hewitt from Craig-Hallum downgraded Lifecore Biomedical to "Hold" with a new price target of $6.28, aligning with the acquisition's cash offer.
• The acquisition by Webster Equity Partners offers shareholders $6.28 in cash per share, with potential Contingent Value Rights (CVRs) up to $9.67 per share, though the deal is currently under investigation for fairness.

Lifecore Biomedical (NASDAQ: LFCR), a prominent biomedical company, recently experienced a significant stock price surge. The stock is currently trading at $6.52 per share, marking an impressive gain of 55.24% for the day. This substantial price movement in the biotech stock market follows major company news. The company's market capitalization, which represents the total value of all its outstanding shares, is now approximately $244.56 million.

Following this development, analyst Matthew Hewitt from Craig-Hallum adjusted his analyst rating on Lifecore Biomedical from "Buy" to "Hold." A "Hold" rating typically indicates that the analyst anticipates the stock will perform in line with the broader market, without expecting significant price increases. A new price target of $6.28 was also established, which was slightly below the current trading price of $6.52.

The change in rating is directly linked to a pivotal acquisition announcement. As reported by GlobeNewswire, Lifecore Biomedical has entered into an agreement to be acquired by Webster Equity Partners. This strategic deal offers shareholders $6.28 in cash for each share they own. This acquisition price precisely matches the new price target set by the analyst, thereby explaining the downgrade to a "Hold" rating for the biomedical stock.

The terms of the acquisition extend beyond just the initial cash payment. Shareholders of Lifecore Biomedical will also be issued Contingent Value Rights (CVRs). These CVRs represent potential future payments that are contingent upon the company achieving specific performance goals. Should all these goals be met, shareholders could potentially receive a total of up to $9.67 per share, valuing the entire transaction at up to $663.7 million.

Despite the premium offered to shareholders, the deal is currently under investigation by law firms Ademi LLP and Halper Sadeh LLC. These firms are scrutinizing whether the buyout price is fair to Lifecore Biomedical shareholders and if the company's board of directors adequately fulfilled its fiduciary duties. As highlighted by GuruFocus, their independent valuation model suggests a fair value of $5.78 for Lifecore Biomedical, indicating that the current offer is modestly overvalued by this metric.